{
  "guideline": {
    "id": "PA166104959",
    "name": "Annotation of DPWG Guideline for tramadol and CYP2D6",
    "source": "DPWG",
    "version": 35,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104959",
    "relatedChemicals": [
      {
        "id": "PA451735",
        "name": "tramadol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302868",
      "name": "Recommendation Annotation PA166302868",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104467,
        "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302877",
      "name": "Recommendation Annotation PA166302877",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104476,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302864",
      "name": "Recommendation Annotation PA166302864",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104463,
        "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302873",
      "name": "Recommendation Annotation PA166302873",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104472,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302869",
      "name": "Recommendation Annotation PA166302869",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104468,
        "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302878",
      "name": "Recommendation Annotation PA166302878",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104477,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302865",
      "name": "Recommendation Annotation PA166302865",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104464,
        "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302874",
      "name": "Recommendation Annotation PA166302874",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104473,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302861",
      "name": "Recommendation Annotation PA166302861",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104460,
        "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative.\nDo not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302870",
      "name": "Recommendation Annotation PA166302870",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104469,
        "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302862",
      "name": "Recommendation Annotation PA166302862",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104461,
        "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302866",
      "name": "Recommendation Annotation PA166302866",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104465,
        "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302875",
      "name": "Recommendation Annotation PA166302875",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104474,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302871",
      "name": "Recommendation Annotation PA166302871",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104470,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302867",
      "name": "Recommendation Annotation PA166302867",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104466,
        "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302876",
      "name": "Recommendation Annotation PA166302876",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104475,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302863",
      "name": "Recommendation Annotation PA166302863",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104462,
        "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302872",
      "name": "Recommendation Annotation PA166302872",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451735",
          "name": "tramadol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104471,
        "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
      },
      "implications": [
        "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "34267337",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).",
      "authors": [
        "Matic Maja",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Houwink Elisa J F",
        "Mulder Hans",
        "Rongen Gerard A P J M",
        "Weide Jan van der",
        "Wilffert Bob",
        "Swen Jesse J",
        "Guchelaar Henk-Jan",
        "Deneer Vera H M",
        "van Schaik Ron H N"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2022
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}